Abstract
A large number of HLA-Cw4 (Cw *0402) peptides were purified, sequenced, and identified from breast and ovarian carcinoma cell lines. HLA-Cw4 molecules were expressed in these cells as soluble, secreted HLA (sHLA) and recovered from the growth medium. The peptides were separated by capillary reversed-phase HPLC and analyzed by tandem mass-spectrometry. The resulting peptides fit to some extent, but not completely, the known consensus of the Cw4 peptide-binding motif. Among the identified peptides, there are a few that originate from proteins of possible interest for cancer immunotherapy or diagnostics, including mucin-5B, ART-1, fatty acid synthase, putative prostate cancer tumor suppressor, DNA topoisomerase-1, and Rac1. This work demonstrates that large-scale identification of HLA peptides recovered from sHLA is an advantageous approach for establishing the HLA peptide consensus of different haplotypes and the identification of useful peptides for treatment of diseases such as cancer, viral, and autoimmune diseases.
This is a preview of subscription content, log in via an institution to check access.
References
Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, Eisenbach L, Zavazava N, Admon A (2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 32:213–222
Bugawan TL, Klitz W, Blair A, Erlich HA (2000) High-resolution HLA class I typing in the CEPH families: analysis of linkage disequilibrium among HLA loci. Tiss Antigens 56:392–404
Buus S (1999) Description and prediction of peptide-MHC binding: the "human MHC project". Curr Opin Immunol 11:209–213
Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716–719
Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N (2000) Metalloproteinases: role in breast carcinogenesis invasion and metastasis. Breast Cancer Res 2:252–257
Falk K, Rotzschke O, Grahovac B, Schendel D, Stevanovic S, Gnau V, Jung G, Strominger JL, Rammensee HG (1993) Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci USA 90:12005–12009
Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261–1263
Husain I, Mohler JL, Seigler HF, Besterman JM (1994) Elevation of topoisomerase I messenger RNA protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539–546
de Jong A (1998) Contribution of mass spectrometry to contemporary immunology. Mass Spectrom Rev 17:311–335
Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 97:3450–3454
Lynch BJ, Bronstein IB, Holden JA (2001) Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J 7:176–180
MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R (1996) Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 35:55–65
Mathijssen RH, Loos WJ, Verweij J, Sparreboom A (2002) Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2:103–123
Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115–2120
Nishizaka S, Gomi S, Harada K, Oizumi K, Itoh K, Shichijo S (2000) A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma. Cancer Res 60:4830–4837
Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo M, Sagiyama K, Naito K (2001) Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet Cytogenet 124:20–26
Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175
Perrais M, Pigny P, Buisine MP, Porchet N, Aubert JP, Van Seuningen-Lempire I (2001) Aberrant expression of human mucin gene MUC5B in gastric carcinoma and cancer cells. Identification and regulation of a distal promoter. J Biol Chem 276:15386–15396
Prilliman K, Lindsey M, Zuo Y, Jackson KW, Zhang Y, Hildebrand W (1997) Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 45:379–385
Prilliman KR, Lindsey M, Jackson KW, Cole J, Bonner R, Hildebrand WH (1998) Complexity among constituents of the HLA-B*1501 peptide motif. Immunogenetics 48:89–97
Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219
Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E (2000) Rac1 in human breast cancer: overexpression mutation analysis and characterization of a new isoform Rac1b. Oncogene 19:3013–2020
Acknowledgement
The Greta Koppel Research Fund for Small-Cell Lung Cancer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buchsbaum, S., Barnea, E., Dassau, L. et al. Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics 55, 172–176 (2003). https://doi.org/10.1007/s00251-003-0570-0
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00251-003-0570-0